<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282412</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD RA ALLO</org_study_id>
    <nct_id>NCT00282412</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism</brief_title>
  <official_title>Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis disease is believed to be due to immune cells, cells that normally&#xD;
      protect the body and are now causing damage to the body. Risk of death is highest in people&#xD;
      with twenty or more joints actively involved with disease, positive rheumatoid factor, an&#xD;
      elevated sedimentation rate (laboratory measures of active inflammation), and patients with&#xD;
      limitation of daily activities (trouble doing simple things like opening a carton of milk).&#xD;
      In these high risk patients, life is significantly shortened. Death is usually from heart&#xD;
      disease, kidney failure, neck dislocation, broken hip bones, or blood clots to the lung. In&#xD;
      this study we use moderate dose chemotherapy (cyclophosphamide and fludarabine) and&#xD;
      CAMPATH-1H (a protein that kills the immune cells that are thought to be causing the&#xD;
      disease), followed by infusion of blood stem cells that have been collected from the&#xD;
      patient's brother or sister (allogeneic stem cell transplant). The purpose of the moderate&#xD;
      dose chemotherapy and CAMPATH-1H is to destroy the cells in the immune system and to allow&#xD;
      the cells from the patient's brother or sister to grow. The purpose of the stem cell infusion&#xD;
      is to restore blood cell production, which will be severely impaired by the moderate dose&#xD;
      chemotherapy and CAMPATH-1H, and to produce a normal immune system that will no longer attack&#xD;
      the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral blood stem cell mobilization (PBSC)&#xD;
&#xD;
      PBSC will be mobilized with G-CSF (dose may be adjusted down to 5-10 ug/kg/day by PI for&#xD;
      toxicity, e.g. flu-like symptoms) with stem cell collection beginning on day 4 or 5.&#xD;
      Leukapheresis may be repeated up to four consecutive days.&#xD;
&#xD;
      Conditioning Regimen Immune Ablation:&#xD;
&#xD;
      Fludarabine 25 mg/m2/d x 5 days (dosage should be based on adjusted body weight) will be&#xD;
      given IV over 30 minutes in 100 cc of normal saline.&#xD;
&#xD;
      Cyclophosphamide 50 mg/kg/d x 4 days (dosage should be based on adjusted body weight) will be&#xD;
      given IV over 1 hour in 500 cc of normal saline.&#xD;
&#xD;
      CAMPATH-1H 30 mg/day x 3 days (no dose adjustment) will be given IV over 2 hours in 100 cc of&#xD;
      normal saline. Premedication with acetaminophen 650mg &amp; benadryl 25-50mg PO/IV will be given&#xD;
      30-60min before infusion. These medications can be repeated as needed.&#xD;
&#xD;
      Hydration approximately 200 cc /hour beginning 6 hours before cyclophosphamide and continued&#xD;
      until 24 hours after the last cyclophosphamide dose.&#xD;
&#xD;
      G-CSF will be continued until absolute neutrophil count reaches 1,000 cells/ml for three&#xD;
      days.&#xD;
&#xD;
      Cyclosporine will be started at 200 mg po BID and adjusted by HPLC levels to between 150-250&#xD;
      or by toxicity (e.g. tremor, renal insufficiency, TTP, etc.). CSA will be continued for 6&#xD;
      months unless stopped for toxicity&#xD;
&#xD;
      Mycophenolate Mofetil (Cellcept) will be given 1 gram po BID and may be adjusted by toxicity&#xD;
      (e.g. cytopenia). Cellcept will be continued for 6 months unless stopped for toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No participant enrolled for three years. No plan to continue study.&#xD;
  </why_stopped>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The number of participants who survived treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Allogeneic Hematopoietic Stem Cell Transplantation</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>inhibits DNA synthesis or repair</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Causes prevention of cell division by forming adducts with DNA</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan, Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath 1H</intervention_name>
    <description>humanized monoclonal antibody against CD52 antigen</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCSF</intervention_name>
    <description>Hematopoietic growth factor</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporins</intervention_name>
    <description>immune suppressive drug</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>CSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>immune suppressive drug</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participant Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 and &lt; 60 years at time of pre-transplant evaluation.&#xD;
&#xD;
          -  An established clinical diagnosis of rheumatoid arthritis by American College of&#xD;
             Rheumatology criteria.&#xD;
&#xD;
          -  Patients must have failed an autologous hematopoietic transplant or have failed to&#xD;
             respond to either methotrexate or leflunomide in combination with a TNF inhibitor.&#xD;
             Failure is defined as an inability to tolerate treatment with at least 6 swollen&#xD;
             joints and 20 involved joints or inability to answer at least 70% of HAQ questions&#xD;
             with &quot;no difficulty&quot; despite 2 or more months of treatment.&#xD;
&#xD;
               -  Ability to give informed consent.&#xD;
&#xD;
               -  Patient must have a HLA matched sibling donor at the A, B, C, and DR loci to&#xD;
                  proceed or HLA matched cord blood donor.&#xD;
&#xD;
               -  If donor is HLA matched cord blood, cord blood stem cells will be obtained from&#xD;
                  the NMDP (1-800-548-1375) and one or two units of HLA matched cord blood will be&#xD;
                  infused on day zero.&#xD;
&#xD;
        Participant Exclusion Criteria&#xD;
&#xD;
          -  History of coronary artery disease, or documented congestive heart failure.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, or any other illness that in the opinion of the&#xD;
             investigators would jeopardize the ability of the patient to tolerate aggressive&#xD;
             chemoradiotherapy.&#xD;
&#xD;
          -  Prior history of malignancy except localized basal cell or squamous skin cancer. Other&#xD;
             malignancies for which the patient is judged to be cured by local surgical therapy,&#xD;
             such as head and neck cancer, or stage I breast cancer will be considered on an&#xD;
             individual basis.&#xD;
&#xD;
          -  Positive pregnancy test, inability or unwillingness to pursue effective means of birth&#xD;
             control, failure to willingly accept or comprehend irreversible sterility as a side&#xD;
             effect of therapy.&#xD;
&#xD;
          -  Psychiatric illness or mental deficiency making compliance with treatment or informed&#xD;
             consent impossible.&#xD;
&#xD;
          -  FEV1/FVC &lt; 70% of predicted, DLCO &lt; 40% of predicted.&#xD;
&#xD;
          -  Resting LVEF &lt; 45 %.&#xD;
&#xD;
          -  Bilirubin &gt; 2.0 mg/dl (unless due to Gilberts), transferase (AST) &gt; 2.5 x upper limit&#xD;
             of normal.&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dl.&#xD;
&#xD;
        Donor Exclusion Criteria&#xD;
&#xD;
          -  Age &lt; 18 years.&#xD;
&#xD;
          -  Positive for HIV-1, HIV-2, HTLV-I, HTLV-II.&#xD;
&#xD;
          -  Active hepatitis B or C.&#xD;
&#xD;
          -  History of a malignancy except for a localized cancer such as skin cancer that is&#xD;
             deemed cured.&#xD;
&#xD;
          -  History of myocardial infarction or congestive heart failure.&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
&#xD;
          -  Current pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2006</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2018</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA&#xD;
Hematopoietic Stem Cell Transplantation: Allogeneic Hematopoietic Stem Cell Transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">Two late deaths non-treatment related. One from pulmonary embolism and one from late leukemia.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA&#xD;
Hematopoietic Stem Cell Transplantation: Allogeneic Hematopoietic Stem Cell Transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.00" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>The number of participants who survived treatment</description>
        <time_frame>up to 5 years</time_frame>
        <population>The number of participants who survived treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA&#xD;
Hematopoietic Stem Cell Transplantation: Allogeneic Hematopoietic Stem Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>The number of participants who survived treatment</description>
          <population>The number of participants who survived treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <desc>All adverse events will be collected at 6 months, 1 year and then yearly up to five years</desc>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA&#xD;
Hematopoietic Stem Cell Transplantation: Allogeneic Hematopoietic Stem Cell Transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <description>Seven months after the transplant, one participant died from pulmonary embolus. Never developed GVHD</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukemia</sub_title>
                <description>One patient was in complete remission, RF neg, no GVHD, stable mixed chimerism, died 4 years after treatment from leukemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Step bovis infection</sub_title>
                <description>One participant had positive step bovis infection post-transplant. Pt had 2 previous step bovis infection prior to transplant. GI workup was negative and was cleared for transplant. The source for recurrent step bovis infection is unclear.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection (UTI)</sub_title>
                <description>One participant had one episode of UTI treated with oral antibiotic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <description>One participant reported two sinus infections, one resolved without treatment, and one treated with oral antibiotic.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects enrolled</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Richard Burt</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-4960</phone>
      <email>rburt@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

